Pfizer and Moderna profited by developing vaccines at a breakneck pace, but should investors add them to their portfolios in 2023?

Did you get Pfizer or Moderna?”

That question came up in countless everyday conversations during the past two years as America got vaxxed and de-masked in an attempt to return to a normal life post-lockdown.

So, let’s look at the two major public companies at the forefront of Operation Warp Speed, the effort to deliver mRNA vaccines to the public as soon as possible.


Although founded in 2010, Moderna (MRNA) wasn’t a household name until 2020. Shares in the biotech firm began trading on the NASDAQ exchange in December 2018, closing the first day at $18.60, 19% below the $23 initial...

Subscribe or sign in to view the rest of this content

All digital content on this site is FREE!

Sign In